← FDA DRUG APPROVALS

FDA ANDA · ANDA212287

PIPERACILLIN AND TAZOBACTAM

Sponsor: ASTRAL

APPLICATION
ANDA212287
TYPE
ANDA
ORIGINAL APPROVAL
2019-07-29
LATEST ACTION
2022-06-22
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

PIPERACILLIN AND TAZOBACTAMDiscontinued
PIPERACILLIN SODIUM EQ 3GM BASE/VIAL, TAZOBACTAM SODIUM EQ 375MG BASE/VIAL · INJECTABLE · INJECTION
PIPERACILLIN AND TAZOBACTAMDiscontinued
PIPERACILLIN SODIUM EQ 4GM BASE/VIAL, TAZOBACTAM SODIUM EQ 500MG BASE/VIAL · INJECTABLE · INJECTION
PIPERACILLIN AND TAZOBACTAMDiscontinued
PIPERACILLIN SODIUM EQ 2GM BASE/VIAL, TAZOBACTAM SODIUM EQ 250MG BASE/VIAL · INJECTABLE · INJECTION

Approval history

2022-06-22Labeling · Supplement 6 · standardAP
2021-02-18Labeling · Supplement 5 · standardAP
2021-02-18Labeling · Supplement 4 · standardAP
2019-07-29UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →